Clinical comparison of 0.6% besifloxacin ophthalmic suspension and 1.5% azithromycin ophthalmic suspension in acute bacterial conjunctivitis
Keywords:
Azithromycin, Besifloxacin, Conjunctivitis, Clinical Resolution
Abstract
Introduction: Acute bacterial conjunctivitis is one of the most common ocular infection seen in day to day clinical practice. Our purpose to conduct this study was to compare the outcome and efficacy of 0.6% besifloxacin ophthalmic suspension and 1.5% azithromycin ophthalmic suspension in acute bacterial conjunctivitis.
Method: This is a Prospective, randomized, parallel-group, clinical study of acute bacterial conjunctivitis Conducted From July 2015 to Sept 2015 on 200 patients in the department of Ophthalmology at Jhalawar Medical College, Jhalawar.(raj.) All selected patients were divided into two groups of 100 each. Group A was treated by besifloxacin 0.6% ophthalmic suspension,where as group B was treated by 1.5% azithromycin ophthalmic suspension three times a day for 7 day. Observation was done on 3, 7 day regarding clinical resolution and side effect of these drugs in both groups.
Result: Clinical resolution, complication , and side effects of these two drugs were analysed on day 3 and day 7 and found that 0.6% besifloxacin is significantly better than 1.5% azithromycin eye drop on day 3 and day 7 (p value<0.5) and also have less side effect (p value<0.5).
Conclusion: 0.6% besifloxacin is safe and efficacious in acute bacterial conjunctivitis in all age group.
Downloads
Download data is not yet available.
References
1. Bremond-Gignac D et al. Efficacy and safety of azithromycin 1.5% eye drops for purulent bacterial conjunctivitis in pediatric patients. Pediatr Infect Dis J 2014;0:1–7. doi:10.1136/bjophthalmol-2013-303888.
2. Mark Abelson, Eugene Protzko, Aron Shapiro, Ana Garces-Soldana and Lyle Bowman.A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis. . Clin Ophthalmol. 2007 Jun; 1(2): 177–182.
3. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract. 2001 Jun;51(467):473-7. [PubMed]
4. S. Khimdas, K.L. Visscher, and C.M.L. Hutnik Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis Ophthalmol Eye Dis. 2011; 3: 7–12. doi: 10.4137/OED.S4102. [PubMed]
5. Isabelle Cochereau, Amel Meddeb‐Ouertani, Moncef Khairallah, Abdelouahed Amraoui, Khalid Zaghloul, Mihai Pop,Laurent Delval, Pascale Pouliquen, Radhika Tandon, Prashant Garg, Pablo Goldschmidt, and Tristan Bourcier.3‐day treatment with azithromycin 1.5% eye drops versus 7‐day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children .Br J Ophthalmol. 2007 Apr; 91(4): 465–469.
6. D G Hwang, D J Schanzlin, M H Rotberg, G Foulks, M B Raizman, and the Levofloxacin Bacterial Conjunctivitis Placebo-controlled Study Group A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis Br J Ophthalmol2003;87:1004–1009)
7. Comstock TL, Karpecki PM, Morris TW, Zhang JZ. Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis. Clin Ophthalmol. 2010 Apr 26;4:215-2. [PubMed]
8. Ranjan Malhotra, Stacey Ackerman , Lynne S. Gearinger , Timothy W. Morris ,The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis. Catherine Allaire Drugs R D (2013) 13:243–252. DOI 10.1007/s40268-013-0029-1. [PubMed]
9. Cambau E, Matrat S, Pan XS, Roth Dit Bettoni R, Corbel C, Aubry A, Lascols C, Driot JY, Fisher LM. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureusand Escherichia coli. J Antimicrob Chemother. 2009 Mar;63(3):443-50. doi: 10.1093/jac/dkn528. Epub 2009 Jan 15.
10. Chaberny IE, Schnitzler P, Geiss HK, Wendt C. An outbreak of epidemic keratoconjunctivtis in a pediatric unit due to adenovirus type 8. Infect Control Hosp Epidemiol. 2003 Jul;24(7):514-9. [PubMed]
11. Abrahamian FM. Update on emerging infections: news from the Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2002;51:205–207. [PubMed]
12. Feingold EK. The outbreak of conjunctivitis at Dartmouth. N Engl J Med. 2003 Jun 19;348(25):2577-8; author reply 2577-8. [PubMed]
13. Buck JM, Lexau C, Shapiro M, Glennen A, Boxrud DJ, Koziol B, Whitney CG, Beall B, Danila R, Lynfield R. A community outbreak of conjunctivitis caused by nontypeable Streptococcus pneumoniae in Minnesota. Pediatr Infect Dis J. 2006;25:906–911.
14. Lichtenstein SJ, Rinehart M; Levofloxacin Bacterial Conjunctivitis Study Group. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. J AAPOS. 2003 Oct;7(5):317-24.
15. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25(5):1159–69. doi: 10.1185/03007990902837919.
16. Karpecki P, Depaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009;31(3):514–26. Doi: 10.1016/j.clinthera.2009.03.010
17. Comstock TL, Paterno MR, Usner DW, Pichichero ME. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adoles- cents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. paediatr Drugs. 2010;12(2):105–12. Doi: 10.2165/11534380-000000000-00000.
18. Comstock TL, Paterno MR, Decory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Clin Drug Investig. 2010;30(10):675–85. Doi: 10.2165/11536720-000000000-00000.
2. Mark Abelson, Eugene Protzko, Aron Shapiro, Ana Garces-Soldana and Lyle Bowman.A randomized trial assessing the clinical efficacy and microbial eradication of 1% azithromycin ophthalmic solution vs tobramycin in adult and pediatric subjects with bacterial conjunctivitis. . Clin Ophthalmol. 2007 Jun; 1(2): 177–182.
3. Sheikh A, Hurwitz B. Topical antibiotics for acute bacterial conjunctivitis: a systematic review. Br J Gen Pract. 2001 Jun;51(467):473-7. [PubMed]
4. S. Khimdas, K.L. Visscher, and C.M.L. Hutnik Besifloxacin Ophthalmic Suspension: Emerging Evidence of its Therapeutic Value in Bacterial Conjunctivitis Ophthalmol Eye Dis. 2011; 3: 7–12. doi: 10.4137/OED.S4102. [PubMed]
5. Isabelle Cochereau, Amel Meddeb‐Ouertani, Moncef Khairallah, Abdelouahed Amraoui, Khalid Zaghloul, Mihai Pop,Laurent Delval, Pascale Pouliquen, Radhika Tandon, Prashant Garg, Pablo Goldschmidt, and Tristan Bourcier.3‐day treatment with azithromycin 1.5% eye drops versus 7‐day treatment with tobramycin 0.3% for purulent bacterial conjunctivitis: multicentre, randomised and controlled trial in adults and children .Br J Ophthalmol. 2007 Apr; 91(4): 465–469.
6. D G Hwang, D J Schanzlin, M H Rotberg, G Foulks, M B Raizman, and the Levofloxacin Bacterial Conjunctivitis Placebo-controlled Study Group A phase III, placebo controlled clinical trial of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis Br J Ophthalmol2003;87:1004–1009)
7. Comstock TL, Karpecki PM, Morris TW, Zhang JZ. Besifloxacin: a novel anti-infective for the treatment of bacterial conjunctivitis. Clin Ophthalmol. 2010 Apr 26;4:215-2. [PubMed]
8. Ranjan Malhotra, Stacey Ackerman , Lynne S. Gearinger , Timothy W. Morris ,The Safety of Besifloxacin Ophthalmic Suspension 0.6 % Used Three Times Daily for 7 Days in the Treatment of Bacterial Conjunctivitis. Catherine Allaire Drugs R D (2013) 13:243–252. DOI 10.1007/s40268-013-0029-1. [PubMed]
9. Cambau E, Matrat S, Pan XS, Roth Dit Bettoni R, Corbel C, Aubry A, Lascols C, Driot JY, Fisher LM. Target specificity of the new fluoroquinolone besifloxacin in Streptococcus pneumoniae, Staphylococcus aureusand Escherichia coli. J Antimicrob Chemother. 2009 Mar;63(3):443-50. doi: 10.1093/jac/dkn528. Epub 2009 Jan 15.
10. Chaberny IE, Schnitzler P, Geiss HK, Wendt C. An outbreak of epidemic keratoconjunctivtis in a pediatric unit due to adenovirus type 8. Infect Control Hosp Epidemiol. 2003 Jul;24(7):514-9. [PubMed]
11. Abrahamian FM. Update on emerging infections: news from the Centers for Disease Control and Prevention. MMWR Morb Mortal Wkly Rep. 2002;51:205–207. [PubMed]
12. Feingold EK. The outbreak of conjunctivitis at Dartmouth. N Engl J Med. 2003 Jun 19;348(25):2577-8; author reply 2577-8. [PubMed]
13. Buck JM, Lexau C, Shapiro M, Glennen A, Boxrud DJ, Koziol B, Whitney CG, Beall B, Danila R, Lynfield R. A community outbreak of conjunctivitis caused by nontypeable Streptococcus pneumoniae in Minnesota. Pediatr Infect Dis J. 2006;25:906–911.
14. Lichtenstein SJ, Rinehart M; Levofloxacin Bacterial Conjunctivitis Study Group. Efficacy and safety of 0.5% levofloxacin ophthalmic solution for the treatment of bacterial conjunctivitis in pediatric patients. J AAPOS. 2003 Oct;7(5):317-24.
15. Tepedino ME, Heller WH, Usner DW, et al. Phase III efficacy and safety study of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis. Curr Med Res Opin. 2009;25(5):1159–69. doi: 10.1185/03007990902837919.
16. Karpecki P, Depaolis M, Hunter JA, et al. Besifloxacin ophthalmic suspension 0.6% in patients with bacterial conjunctivitis: a multicenter, prospective, randomized, double-masked, vehicle-controlled, 5-day efficacy and safety study. Clin Ther. 2009;31(3):514–26. Doi: 10.1016/j.clinthera.2009.03.010
17. Comstock TL, Paterno MR, Usner DW, Pichichero ME. Efficacy and safety of besifloxacin ophthalmic suspension 0.6% in children and adoles- cents with bacterial conjunctivitis: a post hoc, subgroup analysis of three randomized, double-masked, parallel-group, multicenter clinical trials. paediatr Drugs. 2010;12(2):105–12. Doi: 10.2165/11534380-000000000-00000.
18. Comstock TL, Paterno MR, Decory HH, Usner DW. Safety and tolerability of besifloxacin ophthalmic suspension 0.6% in the treatment of bacterial conjunctivitis: data from six clinical and phase I safety studies. Clin Drug Investig. 2010;30(10):675–85. Doi: 10.2165/11536720-000000000-00000.
CITATION
DOI: 10.17511/ijmrr.2015.i11.234
Published: 2015-12-31
How to Cite
1.
Kumar Meena R, Gupta ML. Clinical comparison of 0.6% besifloxacin ophthalmic suspension and 1.5% azithromycin ophthalmic suspension in acute bacterial conjunctivitis. Int J Med Res Rev [Internet]. 2015Dec.31 [cited 2024Nov.22];3(11):1288-93. Available from: https://ijmrr.medresearch.in/index.php/ijmrr/article/view/408
Section
Original Article
OAI - Open Archives Initiative
